Climb Bio (NASDAQ:CLYM) Given New $18.00 Price Target at Oppenheimer

Climb Bio (NASDAQ:CLYM) had its target price upped by Oppenheimer from $10.00 to $18.00 in a research report released on Tuesday,Benzinga reports. The firm currently has an outperform rating on the stock.

CLYM has been the topic of a number of other reports. Robert W. Baird increased their target price on shares of Climb Bio from $9.00 to $12.00 and gave the stock an “outperform” rating in a report on Friday, March 6th. Wedbush initiated coverage on shares of Climb Bio in a report on Thursday, March 5th. They set an “outperform” rating and a $12.00 target price on the stock. Truist Financial initiated coverage on shares of Climb Bio in a report on Tuesday, March 17th. They set a “buy” rating and a $17.00 target price on the stock. Raymond James Financial initiated coverage on shares of Climb Bio in a report on Tuesday, March 10th. They set a “strong-buy” rating and a $25.00 target price on the stock. Finally, Mizuho initiated coverage on shares of Climb Bio in a report on Wednesday, April 15th. They set an “outperform” rating and a $18.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Climb Bio presently has an average rating of “Buy” and an average target price of $16.78.

Climb Bio Price Performance

NASDAQ CLYM opened at $9.37 on Tuesday. Climb Bio has a 12 month low of $1.13 and a 12 month high of $9.90. The company has a market capitalization of $447.60 million, a price-to-earnings ratio of -10.53 and a beta of -0.21. The company’s fifty day moving average price is $7.05 and its two-hundred day moving average price is $4.51.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). As a group, analysts anticipate that Climb Bio will post -1.11 EPS for the current year.

Institutional Trading of Climb Bio

A number of large investors have recently modified their holdings of the company. Peapod Lane Capital LLC increased its holdings in shares of Climb Bio by 0.7% in the 4th quarter. Peapod Lane Capital LLC now owns 565,992 shares of the company’s stock worth $2,264,000 after acquiring an additional 4,126 shares during the period. XTX Topco Ltd increased its holdings in shares of Climb Bio by 19.4% in the 4th quarter. XTX Topco Ltd now owns 34,852 shares of the company’s stock worth $139,000 after acquiring an additional 5,668 shares during the period. Virtu Financial LLC acquired a new stake in shares of Climb Bio in the 4th quarter worth about $43,000. Blair William & Co. IL acquired a new stake in shares of Climb Bio in the 4th quarter worth about $44,000. Finally, Hsbc Holdings PLC increased its holdings in shares of Climb Bio by 107.2% in the 4th quarter. Hsbc Holdings PLC now owns 24,744 shares of the company’s stock worth $99,000 after acquiring an additional 12,800 shares during the period. Institutional investors and hedge funds own 69.76% of the company’s stock.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.